NCT02691936 (VeLVET) is a NA clinical trial of CO2 fractionated vaginal laser in Atrophic Vaginitis, sponsored by The Cleveland Clinic.

Who is sponsoring NCT02691936?

NCT02691936 is sponsored by The Cleveland Clinic.

What drugs are being tested in NCT02691936?

Interventions in NCT02691936: CO2 fractionated vaginal laser, Estrogens, Conjugated (USP).

What condition does NCT02691936 study?

NCT02691936 studies Atrophic Vaginitis, Menopause.

Is NCT02691936 still recruiting?

NCT02691936 is currently completed. Last updated 16 October 2019.

Are results published for NCT02691936?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2019-10-16 · How we verify

NCT02691936: VeLVET

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Randomized Clinical Trial Comparing Vaginal Laser Therapy to Vaginal Estrogen Therapy in Women With Genitourinary Syndrome of Menopause

Completed NA Results posted Last updated 16 October 2019

What this trial tests

NA trial testing CO2 fractionated vaginal laser in Atrophic Vaginitis in 69 participants. Completed in 1 December 2018.

Timeline

1 March 2016

Primary endpoint
1 December 2018

1 December 2018

Quick facts

Lead sponsor	The Cleveland Clinic
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	69
Start date	1 March 2016
Primary completion	1 December 2018
Estimated completion	1 December 2018
Sites	6 locations across United States

Drugs / interventions tested

CO2 fractionated vaginal laser
Estrogens, Conjugated (USP) — full drug profile →

Conditions studied

Atrophic Vaginitis — all drugs for Atrophic Vaginitis →
Menopause — all drugs for Menopause →

Sponsor

The Cleveland Clinic

Who can join

Eligibility, female only, with Atrophic Vaginitis or Menopause. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Vaginal Dryness
Time frame: 6 months
Vaginal dryness was assessed using a score of 0 (minimum) and 10 (maximum) on a Visual Analog Scale (VAS). Data presented is the mean difference before and after treatment. A higher mean difference signifies that the vaginal dryness score decreased to a greater measure hence resulting in a better outcome.

Sponsor's own description

This is a multi-centered, randomized prospective single blinded clinical trial comparing CO2 fractionated vaginal laser therapy and vaginal estrogen cream therapy in the treatment of vulvovaginal atrophy/GSM.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Energy-based interventions for genitourinary syndrome of menopause: a systematic review of randomized controlled trials and prospective observational studies.
Zerzan NL, Greer N, Ullman KE, Sowerby C, et al · · 2025 · cited 2× · PMID 39774067 · DOI 10.1097/gme.0000000000002465

Verify or expand the search:

Other The Cleveland Clinic trials

Trials by the same sponsor.

NCT07218198 — Clinical Decision Support Tool for the Treatment of Uncontrolled Hypertension · NA · not yet recruiting
NCT07442747 — Neural Mechanisms of Aerobic Exercise Benefits in PD With DBS · NA · not yet recruiting
NCT07471464 — Centered Surgery - Preoperative Counseling and Patient Satisfaction · recruiting
NCT07073963 — Virtual Patient Groups for Sarcoidosis Associated Fatigue · NA · recruiting
NCT07363343 — Nifedipine and Enalapril vs Nifedipine and Labetalol for the Treatment of Postpartum Hypertension Study · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02691936 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The Cleveland Clinic
Last refreshed: 16 October 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02691936.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing